High relapse rate seen at week 72 for patients treated with R1626 combination therapy†

Open Access

Publisher Website

26 September 2008

journal article
other
Published by Wolters Kluwer Health in Hepatology

Vol. 48 (4) , 1349-1350
https://doi.org/10.1002/hep.22593

Abstract

No abstract available

Keywords

This publication has 2 references indexed in Scilit:

R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin†
Hepatology, 2008
Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
Annals of Internal Medicine, 2004